After internet hosting the go to of Prime Minister of United Kingdom Boris Johnson to its Wrexham facility in North Wales on November 30, 2020, Wockhardt Ltd. has supplied its vaccine manufacturing facility in Aurangabad to the Indian authorities or every other vaccine developer for mass manufacturing of vaccines to counter COVID-19.
The U.Okay. Government has reserved one fill and end manufacturing line at Wockhardt UK for its unique use for 18 months with the intention to assure the provision of vaccines required to battle towards COVID-19. It has been contracted to manufacture 100 million items of Oxford vaccine being developed by AstraZenaca.
Stating that there can be demand for vaccines in India and world wide Dr. Habil Khorakiwala, founder chairman, Wockhardt Ltd., stated, “We have a billion dosage capacity for both API & fill finish in India which can be used to manufacture vaccines. We can be partner with the Indian government or any vaccine developers to fight the world’s most demanding need of the hour in COVID-19.”
He stated the corporate must make minimal funding to get the facility able to manufacture COVID-19 vaccine. He stated there can be huge demand and the corporate also can make the drug substance for the vaccine as effectively apart from endeavor fill and end manufacturing.
“The facility is available and it is possible to re arrange as per requirement. We have already made 95% of the investment and we can ramp up capacity at the shortest possible time to bridge the demand and supply gap” he stated in a press convention.
Currently, Wockhardt shouldn’t be within the authorities’s checklist to manufacture COVID-19 vaccine for the Indian market.
Besides the Indian authorities, the corporate is speaking to some international corporations who is likely to be to manufacture vaccines in India.
“If any time in the future if the Indian government wants anything to be done, we can extend support,” Mr. Khorakiwala stated.